Torasemide solution
Torasemide solution is mainly composed of Torasemide (HY-B0247). Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 56211-40-6
- Formule: C16H20N4O3S
- Masse moléculaire:348.42
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Chemical Information
-
CAS No. 56211-40-6
-
Masse moléculaire 348.42
-
Formule C16H20N4O3S
-
SMILES
O=S(C1=C(C=CN=C1)NC2=CC=CC(C)=C2)(NC(NC(C)C)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
Références
[1]. Ishido, H., et al. Torasemide for the Treatment of Heart Failure. Cardiovascular & Hematological Disorders-Drug Targets. 2008. 8(2), 127–132. [Content Brief]
[2]. Goodfriend, T. L., et al. Torsemide inhibits aldosterone secretion in vitro. Life Sciences. 1998. 63(3), PL45–PL50. [Content Brief]
[3]. H A Friedel, et al. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991 Jan;41(1):81-103. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Torasemide solution Related Classifications
HY-FLB0247 Related Classifications
Powered by Bioz